According to the US Centers for Disease Control and Prevention and the Food and Drug Administration, 2.8 million antibiotic-resistant infections occur annually in the US, resulting in 35,000 deaths. Combating AMR requires multifaceted efforts in both the healthcare and veterinary sectors.
In response to this critical public health threat, scientists at Purdue University are working together to increase awareness and discover solutions for advanced diagnostics, treatment, and prevention.
Dr. Vieira is a microbiologist and veterinarian specializing in infectious diseases, antimicrobial resistance (treatment and prevention), proteomics, and metabolomics related to animal biology and physiology. As a Postdoctoral Research Associate at Purdue University, under the mentoring of Dr. Figueiredo and Dr. Sintim, his goal is to advance drug discovery against Antimicrobial Resistance, with novel compound testing in models of skin and bone infections by Gram-positive and Gram-negative bacteria.
Dr. Figueiredo is an Associate Professor at the Department of Basic Medical Sciences (BMS), Purdue University. Dr. Figueiredo has a BS in Biological Sciences from Univ. Federal de Goiás (Brazil) and a PhD from the Univ. of Wisconsin-Madison in Cell and Molecular Biology. Dr. Figueiredo’s lab conducts multidisciplinary research spanning the fields of molecular biology, gene delivery, and osteo-immune therapeutics. Current projects focus on targeting bone and inflammatory environments with IL-27 therapy via gene delivery and preclinical translation of novel strategies for treatment of skin and bone infections by multidrug resistant organisms in collaboration with Dr. Sintim and Dr. Greenfield (IU).
Dr. Sintim obtained his BSc from University College London (Medicinal Chemistry). He did his DPhil in organic chemistry at University of Oxford under Prof. David Hodgson. He held postdoctoral positions at Oxford and Stanford Universities (with Profs Tim Donohoe and Eric Kool respectively) before joining the University of Maryland at College Park (UMD) in 2006 as an Assistant Professor. In 2012, Herman received tenure and was promoted to Associate Professor. In 2015, Herman was promoted to the rank of Professor at UMD. In October 2015, Herman was awarded an endowed professorship in drug discovery at Purdue University and moved his group to Purdue. In 2017, Herman co-founded KinaRx LLC. From 2020 to 2022, Herman served as Program Director at the NSF (Chemistry). In 2022, Herman became the Richard B. Wetherill Professor of Chemistry and Drug Discovery. The Sintim lab is committed to drug discovery to find better and more effective ways to prevent, treat, and/or control multi-drug resistant infections.
Dr. HogenEsch is Professor in the Department of Comparative Pathobiology and Associate Dean for Research and Graduate Programs in the College of Veterinary Medicine. He grew up in the Netherlands and earned his DVM degree cum laude from the University of Utrecht in 1984. He did his graduate training in immunology at the University of Illinois at Urbana-Champaign, and received his PhD in 1989. He is board-certified by the American College of Veterinary Pathologists since 1989. The HogenEsch lab works on vaccine adjuvants and delivery systems to improve the immune response to vaccines.